Orenes-Piñero Esteban, Ruiz-Nodar Juan M, Esteve-Pastor María Asunción, Quintana-Giner Miriam, Rivera-Caravaca José Miguel, Veliz Andrea, Valdés Mariano, Macías Manuel, Pernias-Escrig Vicente, Vicente-Ibarra Nuria, Carrillo Luna, Sandín-Rollán Miriam, Candela Elena, Lozano Teresa, Marín Francisco
Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, (IMIB-Arrixaca), Universidad de Murcia, Murcia, Spain.
Department of Cardiology, Hospital General Universitario de Alicante, Alicante, Spain.
Oncotarget. 2017 Sep 24;8(46):80182-80191. doi: 10.18632/oncotarget.21260. eCollection 2017 Oct 6.
Elderly represents a subgroup of high-risk ACS patients due to their advanced age and other comorbidities. Unfortunately, they are also often under-represented in many studies and clinical trials. Furthermore, cardiologists commonly find difficulties in the choice of the antiplatelet treatment and even on whether invasive revascularization should be used. In this study, the management of elderly ACS patients regarding antiplatelet therapy and revascularization procedures will be analyzed.
1717 ACS patients were consecutively included in this study from 3 tertiary Hospitals in the Southeast of Spain. Of them, 529 (30.8%) were ≥ 75 years. They were mainly male (60.7%) with a mean age of 81.4±4.7 years. Clinical characteristics, treatment received (antiaplatelet therapy, revascularization) and outcome were analyzed.
Regression analysis showed that being ≥ 75 years is independently associated with neither performing catheterization (79.6% 97.1%), nor revascularization (51.8% 72.5%), being the medical conservative treatment the election in these elderly patients (40.6% 18.9%) ( < 0.001 for all). Furthermore, ticagrelor prescription were significantly decreased in older patients (11.5% 19.6%; < 0.001). Regarding patients outcome after one-year of follow-up, being ≥ 75 years was associated with death, major adverse cardiac events (MACE) and major bleeding (all of them < 0.001). Importantly, nor performing catheterization was independently associated with MACE and death in Cox multivariate analysis in elderly patients.
Elderly patients with ACS are undertreated both invasively and pharmacologically, and this fact might be associated with the observed worse outcomes.
由于高龄及其他合并症,老年患者是高危急性冠状动脉综合征(ACS)患者的一个亚组。不幸的是,他们在许多研究和临床试验中的代表性往往不足。此外,心脏病专家在选择抗血小板治疗甚至是否应采用侵入性血运重建方面通常也存在困难。在本研究中,将分析老年ACS患者在抗血小板治疗和血运重建程序方面的管理情况。
本研究连续纳入了西班牙东南部3家三级医院的1717例ACS患者。其中,529例(30.8%)年龄≥75岁。他们主要为男性(60.7%),平均年龄为81.4±4.7岁。分析了临床特征、接受的治疗(抗血小板治疗、血运重建)及结局。
回归分析显示,年龄≥75岁与进行导管插入术(79.6%对97.1%)或血运重建(51.8%对72.5%)均无独立相关性,这些老年患者选择的是药物保守治疗(40.6%对18.9%)(所有P均<0.001)。此外,老年患者替格瑞洛的处方显著减少(11.5%对19.6%;P<0.001)。关于随访1年后的患者结局,年龄≥75岁与死亡(均P<0.001)、主要不良心脏事件(MACE)及大出血相关。重要的是,在老年患者的Cox多变量分析中,未进行导管插入术与MACE及死亡独立相关。
老年ACS患者在侵入性治疗和药物治疗方面均未得到充分治疗,这一事实可能与观察到的较差结局相关。